GRASSP
The Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP).
PURPOSE OF THE MEASURE
The GRASSP was developed with the intent to be a clinical and a
research tool that would:
- capture information on upper limb impairment from the traumatic tetraplegic population
- obtain integrated sensory and motor impairment data, and discriminate the population according to impairment and function
- be responsive (sensitive) to change over time
- assess the extent of spontaneous (natural) recovery
- be applied in clinical settings and in clinical trials/studies to evaluate the effect of novel interventions
RECOMMENDED USE
The GRASSP is recommended for use in the early acute phase to any point in the post-injury time-course, particularly when a change in neurological status is the construct of interest. The GRASSP is intended for use with traumatic cervical SCI patients that are being followed for recovery of the upper limb. The GRASSP V1 is not designed for the non-traumatic SCI populations, pediatric population or SCI candidates undergoing tendon transfer/peripheral nerve transfer surgery as yet. Further development is required for the GRASSP to meet the needs of these specific groups.
The GRASSP measure is for use by clinicians in the clinical setting as a clinical outcome measure, researchers in the clinical/research setting as a primary or secondary outcome measure, and academics who are involved in investigator driven research. The developers and funding agencies that have supported GRASSP development would like to promote widespread use in both clinical and research settings. If you are interested in purchasing a GRASSP Kit please go to Products and Purchasing tab now.
VERSIONS of GRASSP
The original version is GRASSP Version 1, which is the version currently in use worldwide. Recently the GRASSP Research and Development Group (GRDG) has been working to launch version 2 which is also specific to traumatic SCI. In addition the GRDG is working on a version for cervical myelopathy related to non-traumatic causes; and field testing of versions for pediatric patients and patients undergoing tendon transfer surgery are in progress. See development tab for more information on Versions.
DISCLOSURE
GRASSP ver. 1, 2, and Myelopathy are non-medical, outcome measuring, and manually operative devices. These devices do not require any electric, electronic, chemical, magnetic power nor do they need any intravenous administration to operate. Since its design, manufacturing, packaging, and usage are known to be non-hazardous and safe for its users and administrators, the device is exempted from a CE or FDA certification.
For further information please refer the websites below:
https://www.nibusinessinfo.co.uk/content/products-need-ce-marking
http://tradecommissioner.gc.ca/world-monde/133383.aspx?lang=eng#Find
Although measuring equipment is mentioned as a category of products requiring CE certification, this refers to products that require calibration and/or are electronically powered. Again, the GRASSP or parts do not fall into these categories.